We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M Turnover 44%
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
-17.28%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$222M
AUM Growth
-$86.4M
Cap. Flow
-$39.4M
Cap. Flow %
-17.74%
Top 10 Hldgs %
33.77%
Holding
109
New
40
Increased
8
Reduced
21
Closed
35
Avg Time Held Equity + Options
0.3 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.1 years
Avg Time Held Equity only
0.3 years
Top 10 Avg Time Held Equity only
0.2 years
Top 20 Avg Time Held Equity only
0.2 years

Sector Composition

Rank Sector Weight
1 Healthcare 85.27%
2 Miscellaneous 14.73%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
AGN
1
DELISTED
Allergan plc
AGN
$10.2M 4.59%
37,500
-7,500
-17% -$2.3M
2014 Q2
5 quarters
NUVA
2
DELISTED
NuVasive
NUVA
$8.44M 3.8%
175,000
-60,000
-26% -$3.1M
2014 Q3
4 quarters
FPRX
3
DELISTED
Five Prime Therapeutics
FPRX
$7.7M 3.46%
500,000
+75,000
+18% +$1.61M
2015 Q1
2 quarters
MNK
4
DELISTED
Mallinckrodt
MNK
$7.67M 3.45%
+120,000
New +$11.9M
2015 Q3
0 quarters
ZLTQ
5
DELISTED
Zeltiq Aesthetics
ZLTQ
$7.53M 3.39%
235,000
+85,000
+57% +$2.81M
2014 Q3
4 quarters
NSTG
6
DELISTED
NanoString Technologies
NSTG
$7.2M 3.24%
450,000
+50,000
+13% +$783K
2014 Q1
6 quarters
AMGN icon
7
Amgen
AMGN
$250B
$6.92M 3.11%
+50,000
New +$7.88M
2015 Q3
0 quarters
GILD icon
8
Gilead Sciences
GILD
$208B
$6.87M 3.09%
+70,000
New +$7.77M
2015 Q3
0 quarters
CELG
9
DELISTED
Celgene
CELG
$6.49M 2.92%
+60,000
New +$7.45M
2015 Q3
0 quarters
ALNY icon
10
CALL
Alnylam Pharmaceuticals
ALNY
$21.4B
$6.03M 2.71%
+75,000
New +$8.33M
2015 Q3
0 quarters
BMY icon
11
CALL
Bristol-Myers Squibb
BMY
$129B
$5.92M 2.66%
+100,000
New +$6.34M
2015 Q3
0 quarters
AVDL
12
DELISTED
Avadel Pharmaceuticals
AVDL
$5.71M 2.57%
350,000
-225,000
-39% -$4.96M
2014 Q4
3 quarters
EW icon
13
Edwards Lifesciences
EW
$61.6B
$5.69M 2.56%
+240,000
New +$5.79M
2015 Q3
0 quarters
HZNP
14
DELISTED
Horizon Therapeutics
HZNP
$5.45M 2.45%
275,000
+75,000
+38% +$2.37M
2015 Q2
1 quarter
CYH icon
15
Community Health Systems
CYH
$300M
$5.13M 2.31%
+145,200
New +$6.66M
2015 Q3
0 quarters
ZGNX
16
DELISTED
Zogenix
ZGNX
$5M 2.25%
+370,000
New +$6.67M
2015 Q3
0 quarters
HTWR
17
DELISTED
Heartware International
HTWR
$4.71M 2.12%
+90,000
New +$6.84M
2015 Q3
0 quarters
IART icon
18
Integra LifeSciences
IART
$1.09B
$4.47M 2.01%
+150,000
New +$4.69M
2015 Q3
0 quarters
ARCT icon
19
Arcturus Therapeutics
ARCT
$240M
$4.16M 1.87%
98,423
+12,709
+15% +$669K
2015 Q1
2 quarters
GNMK
20
DELISTED
GenMark Diagnostics
GNMK
$4.13M 1.86%
525,000
-225,000
-30% -$2.08M
2015 Q2
1 quarter
DVAX icon
21
DELISTED
Dynavax Technologies
DVAX
$4.05M 1.82%
+165,000
New +$4.67M
2015 Q3
0 quarters
HCA icon
22
HCA Healthcare
HCA
$107B
$3.87M 1.74%
+50,000
New +$4.43M
2015 Q3
0 quarters
AEGR
23
DELISTED
Aegerion Pharmaceuticals
AEGR
$3.4M 1.53%
+250,000
New +$4.45M
2015 Q3
0 quarters
PCRX icon
24
Pacira BioSciences
PCRX
$1.46B
$3.29M 1.48%
+80,000
New +$4.9M
2015 Q3
0 quarters
ISRG icon
25
Intuitive Surgical
ISRG
$152B
$3.22M 1.45%
63,000
-117,000
-65% -$6.63M
2015 Q2
1 quarter

Similar funds

Ghost Tree Capital's Q3 2015 Portfolio in Review

As of Q3 2015, Ghost Tree Capital held 109 positions worth $222M, down 28% from $309M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ghost Tree Capital withdrew a net $39.4M in Q3 2015, closing 35 positions and reducing 21 holdings. Its most notable exit was Biogen, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Ghost Tree Capital opened a new position in Mallinckrodt worth $7.67M.

  • Ghost Tree Capital's largest Q3 2015 buy was Mallinckrodt: 120,000 shares worth $7.67M.
  • Ghost Tree Capital added most to Zeltiq Aesthetics in Q3 2015, an estimated $2.81M increase.
  • Ghost Tree Capital's biggest Q3 2015 reduction was Portola Pharmaceuticals, cutting an estimated $7M.
  • Ghost Tree Capital fully exited Biogen in Q3 2015, selling an estimated $12.1M.
  • Ghost Tree Capital's ten largest holdings make up 34% of its $222M portfolio in Q3 2015.
  • Ghost Tree Capital opened 40 new positions and closed 35 in Q3 2015.
  • Ghost Tree Capital's portfolio value fell 28% quarter-over-quarter to $222M.

Based on Ghost Tree Capital's 13F filing for Q3 2015, filed 16 Nov 2015.